ORIC PHARMACEUTICALS, INC. Cash and Restricted Cash
ORIC PHARMACEUTICALS, INC. (ORIC) had Cash and Restricted Cash of $37.97 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $37.97M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56.89M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46.16M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $50.16M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $37.97M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $56.89M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $46.16M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $50.16M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $76.36M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $49.83M 10-Q · filed 2026-05-04 |
| 2024-12-31 | $59.90M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $44.72M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $50.32M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $56.85M 10-Q · filed 2025-05-05 |
| 2023-12-31 | $23.88M 10-K · filed 2026-02-23 |
| 2023-09-30 | $26.73M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $104.17M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $59.46M 10-Q · filed 2024-05-06 |
| 2022-12-31 | $67.31M 10-K · filed 2025-02-18 |
| 2022-09-30 | $29.54M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $49.55M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $113.11M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $226.47M 10-K · filed 2024-03-11 |
| 2021-09-30 | $241.59M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $170.08M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $104.21M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $78.45M 10-K · filed 2023-03-16 |
| 2020-09-30 | $62.03M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $196.64M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $79.44M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $89.16M 10-K · filed 2022-03-21 |
| 2019-09-30 | $96.42M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $96.31M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $52.27M 10-Q · filed 2020-05-20 |
| 2018-12-31 | $42.64M 10-K · filed 2022-03-21 |
| 2017-12-31 | $25.82M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |